WHO expects results from COVID-19 drug trials in 2 weeks, says Dr Tedros Adhanom

WHO Director-General Tedros ham Ghebreyesus on June 3 said that results from clinical trials it is conducting of drugs that might be effective in treating COVID-19 patients can be expected soon. According to reports, WHO was conducting clinical trials for drugs that will be effective in treating COVID-19 and has recruited over 5,000 patients spanning over 39 countries.

WHO close to concrete results

As per reports, Director-General has claimed that preliminary results can be expected in next two weeks. Reportedly, Solidarity Trial started out in five parts looking at possible treatment approaches to COVID-19: first is standard care of infected patient, second is a drug called remdesivir, third involves testing viability of hydroxychloroquine, anti-malaria drug which was championed by US President Donald Trump. fourth is testing of HIV drug lopinavir/ritonavir and last st involves combining lopinavir/ritonavir with interferon.

According to reports, WHO has stopped testing hydroxychloroquine after it was proven that anti-malaria drug has benefit for those who have disease, but furr study is still needed when it comes to determining wher drug has benefits as a form of preventive medication.

Re: COVID-19 Vaccine By Ahmedab-based Zydus Cila Gets DCGI d For Human Clinical Trials

Re: Potential COVID-19 Vaccine By Zydus Cila Gets DCGI d For Human Clinical Trials

He of WHO’s emergencies programme, Mike Ryan, h said that it would be unwise to predict when a vaccine for dely coronavirus could be rey. He ded that even if a promising vaccine candidate was discovered, question was how soon it could be mass-produced.

While re is vaccine for COVID-19 at moment, 18 potential vaccines are being tested on humans by different companies worldwide.

Re: Zydus Gets d For Human Trials Of COVID-19 Vaccine

Re: Horseshoe Crab Blood To Be Utilised By Swiss Pharmaceutical Lonza For COVID-19 Vaccine

Blood of horse shoe crab a possible cure

As per reports, Swiss multinational, chemicals, and biotechlogy company Lonza, will manufacture a COVID-19 vaccine with horseshoe crab blood this month. Horseshoe crab blood is used by several pharmaceuticals because it contains a natural source of Limulus amebocyte lysate, a substance that helps to detect presence of a contaminant called endotoxin. This contaminant is capable of making its way into vaccines, injectable drugs, or or sterile pharmaceuticals such as artificial knees and hips. presence of endotoxins in drugs can severely dam human health. Hence it is necessary to use horseshoe crab blood to detect its presence.

(Im Credit AP)